The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) increased by $0.02 on Tuesday to $1.74, up 0.87 percent. The last five days have seen an average of 1,095,099 shares of common stock traded. 13 times new highs were reached in the current year, with a fall of -$1.6600. The average number of shares traded over the last 20 days was 2,198,195, while the average volume over the last 50 days totaled 3,287,238.
KPTI stock appreciated 13.40% since last month. On 07/19/23, the company’s shares reached a one-month low of $1.4400. The stock touched a high of $6.01 on 04/17/23, after rallying from a low of $1.44 in 52 weeks. The price of KPTI stock has declined by -48.97% or -$1.6600 this year, reaching a new high 13 times. Still, the stock price is down -71.13% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
KPTI stock investors should be aware that Karyopharm Therapeutics Inc. (KPTI) stock had its last reported insider trading activity 8 days ago on Aug 07. On Aug 07, President and CEO Paulson Richard A. sold 3,722 shares at $1.72 each. This transaction resulted in the insider making $6,402. On Jul 28, Poulton Stuart sold 2,845 shares at a price of US$1.70. After the transaction, the insider now owns 156,286 shares. President and CEO Paulson Richard A. had earlier sold 3,538 shares on Jul 05 for $1.72 a share. The transaction was completed for $6,085.
Financial Health
For the three months ended June 29, Karyopharm Therapeutics Inc.’s quick ratio was 4.90, while its current ratio was 4.90, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 96.30% percent. Karyopharm Therapeutics Inc.’s EBITDA margin for the year ended June 29 was -90.14%, whereas its operating margin stood at -85.70% for the same period. Based on annual data, it had gross profit of $151.86 million and revenue of $157.07 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. KPTI’s return on assets (ROA) during the last 12 months has been -46.70%. There was a -49.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 207.20%.
Earnings Surprise
According to Karyopharm Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $155.87 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $37.58 million, while revenues fell by -5.59% to $38.7 million. It was predicted that Karyopharm Therapeutics Inc.’s quarterly earnings would be -$0.29, but it ended up being -$0.34, beating the consensus by 14.70%. EBITDA was -$30.31 million for the quarter. At the end of Karyopharm Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 369.08 million, while its total debt was $310.8 million. Equity owned by shareholders amounts to $114.36 million.
Technical Picture
Here’s a quick look at Karyopharm Therapeutics Inc.’s (KPTI) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 55.39%, suggesting the stock is Neutral, with a 51.39% historical volatility rate.
The stochastic %K and %D were 52.26% and 46.53% respectively, while the average true range (ATR) was 0.1179. Based on the 14-day stochastic reading of 52.54%, the RSI (14) reading is 50.31%. On the 9-day MACD Oscillator, the stock is at 0.0267.
Analyst Ratings
In its analyst report released on January 19, 2023, Piper Sandler began covering Karyopharm Therapeutics Inc. (NASDAQ: KPTI). The stock was rated as an Overweight by the brokerage firm.
